Literature DB >> 1871329

Involvement of M1 and M2 muscarinic receptors of the basal forebrain in cholinergically mediated changes in the rat locomotion.

S M Brudzynski1, R S McLachlan, J P Girvin.   

Abstract

1. Wistar rats were implanted with cannulae into the medial preoptic and anterior hypothalamic areas for intracerebral injections. 2. Unilateral intracerebral injections of carbachol (1 microgram) into a limited area of the basal forebrain decreased significantly both the distance travelled by the animals and time spent walking. 3. In addition to the decrease in locomotion, it was demonstrated for the first time that injections of carbachol also slow animal movement by significantly decreasing speed of forward progression. 4. All locomotor effects of carbachol were reversed by local pretreatment with atropine (1 microgram) but not by pirenzepine (2 micrograms) suggesting that these effects were mediated by M2 muscarinic receptors with minimal or no M1 receptor involvement.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1871329     DOI: 10.1016/0278-5846(91)90093-g

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  3 in total

Review 1.  The ascending mesolimbic cholinergic system--a specific division of the reticular activating system involved in the initiation of negative emotional states.

Authors:  Stefan M Brudzynski
Journal:  J Mol Neurosci       Date:  2013-11-24       Impact factor: 3.444

2.  Mutation causing autosomal dominant nocturnal frontal lobe epilepsy alters Ca2+ permeability, conductance, and gating of human alpha4beta2 nicotinic acetylcholine receptors.

Authors:  A Kuryatov; V Gerzanich; M Nelson; F Olale; J Lindstrom
Journal:  J Neurosci       Date:  1997-12-01       Impact factor: 6.167

Review 3.  Pharmacology of Ultrasonic Vocalizations in adult Rats: Significance, Call Classification and Neural Substrate.

Authors:  Stefan M Brudzynski
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.